Susquehanna International Group, LLP Fennec Pharmaceuticals Inc. Put Options Transaction History

Susquehanna International Group, LLP

  • $527 Billion
  • Q2 2024

Put Options

5 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q3 2023

Nov 14, 2023
SELL
$7.15 - $8.94 $92,235 - $115,326
-12,900 Reduced 51.39%
12,200 $91,000
Q2 2023

Aug 11, 2023
SELL
$7.27 - $9.82 $61,795 - $83,470
-8,500 Reduced 25.3%
25,100 $221,000
Q1 2023

May 16, 2023
BUY
$7.38 - $10.35 $103,320 - $144,900
14,000 Added 71.43%
33,600 $279,000
Q4 2022

Feb 14, 2023
SELL
$7.63 - $10.22 $379,211 - $507,934
-49,700 Reduced 71.72%
19,600 $188,000
Q3 2022

Nov 14, 2022
SELL
$5.71 - $8.54 $292,352 - $437,247
-51,200 Reduced 42.49%
69,300 $561,000

Others Institutions Holding FENC

# of Institutions
65
Shares Held
14.3M
Call Options Held
10K
Put Options Held
83.8K
View Full List

About FENNEC PHARMACEUTICALS INC.

FENC Quotes by TradingView
  • Ticker FENC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 26,067,300
  • Market Cap $130M
  • Description
  • Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec...
More about FENC
Track This Portfolio

Track Susquehanna International Group, LLP Portfolio

Follow Susquehanna International Group, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email